Sanofi teams up with AI-driven drug discovery firm

14 March 2024

Germany-based AI-driven drug discovery company Partex Group has announced a collaboration with French pharma major Sanofi (Euronext: SAN).

Building upon the success of a pilot project conducted in 2022, this new collaboration centers around the expansion of an innovative approach which leverages Partex's AI arm, Innoplexus, and its proprietary AI technology to identify new indications within Sanofi's out-licensing portfolio.

"We aspire to unlock the hidden potential within Sanofi's out-licensing portfolio"Through meticulous indication expansion, prioritization, and lab validation studies, the partners will seek to uncover fresh prospects for Sanofi’s out-licensing portfolio.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK